CompletedNCT00303602
Dissolving olanzapine or tablets and weight gain
About this title
Read the official source — NCT00303602Medication studyAges 18–65Multiple countriesSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Escondido and 20 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateMarch 2006
- Recruitment status
- Completed
- Enrollment listed in the registry
- 149
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States, Canada, Mexico, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00303602
- Official title
Show the full official title
BMI Evaluation: Placebo and Active Comparator Trial of Olanzapine Zydis Pills Used Sublingually (PLATYPUS)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Escondido, United States · Garden Grove, United States · National City, United States
18 more locations
- Orange, United States
- Atlanta, United States
- Las Vegas, United States
- Staten Island, United States
- Penticton, Canada
- Winnipeg, Canada
- Dartmouth, Canada
- Halifax, Canada
- Sydney, Canada
- Chatham, Canada
- Greater Sudbury, Canada
- Kingston, Canada
- Windsor, Canada
- Sherbrooke, Canada
- Mexico City, Mexico
- Amersfoort, Netherlands
- Rotterdam, Netherlands
- San Juan, Puerto Rico
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Did this study involve medication?
Yes. The study involved medication, including Sublingual orally disintegrating olanzapine (SODO) and Oral olanzapine.
Who was this study for?
Listed age limits: 18 years to 65 years.
